

# Robert A Sandhaus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6193802/publications.pdf>

Version: 2024-02-01

30  
papers

1,302  
citations

758635

12  
h-index

454577

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1614  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intravenous augmentation treatment and lung density in severe $\alpha_1$ antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015, 386, 360-368.	6.3	408
2	Delay in Diagnosis of $\alpha_1$ -Antitrypsin Deficiency. <i>Chest</i> , 2005, 128, 1989-1994.	0.4	196
3	The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2016, 3, 668-682.	0.5	148
4	Trends in the Diagnosis of Symptomatic Patients With $\alpha_1$ -Antitrypsin Deficiency Between 1968 and 2003. <i>Chest</i> , 2005, 128, 1179-1186.	0.4	130
5	The Prevalence of Alpha-1 Antitrypsin Deficiency Among Patients Found to Have Airflow Obstruction. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 352-358.	0.7	51
6	$\alpha_1$ -Antitrypsin Augmentation Therapy for $\text{PI}^*\text{MZ}$ Heterozygotes. <i>Chest</i> , 2008, 134, 831-834.	0.4	50
7	Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. <i>Medical Hypotheses</i> , 2021, 146, 110394.	0.8	42
8	The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2017, 4, 34-44.	0.5	42
9	A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. <i>Clinical Genetics</i> , 2018, 94, 502-511.	1.0	33
10	Alpha-1-Antitrypsin Enhances Primary Human Macrophage Immunity Against Non-tuberculous Mycobacteria. <i>Frontiers in Immunology</i> , 2019, 10, 1417.	2.2	29
11	Clinical considerations in individuals with $\alpha_1$ -antitrypsin $\text{PI}^*\text{SZ}$ genotype. <i>European Respiratory Journal</i> , 2020, 55, 1902410.	3.1	27
12	&lt;p&gt;An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency&lt;/p&gt;. <i>International Journal of COPD</i> , 2019, Volume 14, 2089-2101.	0.9	14
13	Patient Involvement in the Design of a Patient-Centered Clinical Trial to Promote Adherence to Supplemental Oxygen Therapy in COPD. <i>Patient</i> , 2016, 9, 271-279.	1.1	13
14	Comparing Patients with ZZ Versus SZ Alpha-1 Antitrypsin Deficiency: Findings from AlphaNetâ€™s Disease Management Program. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2019, 6, 29-39.	0.5	12
15	Genotype is associated with smoking and other key health behaviors among individuals with alpha-1 antitrypsin deficiency-associated lung disease. <i>Respiratory Medicine</i> , 2018, 143, 48-55.	1.3	11
16	Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2019, 6, 6-16.	0.5	11
17	&lt;p&gt;New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 345-355.	0.9	10
18	Benefits Among Patients with Alpha-1 Antitrypsin Deficiency Enrolled in a Disease Management and Prevention Program. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2017, 4, 56-64.	0.5	10

#	ARTICLE	IF	CITATIONS
19	Quantitative disease progression model of $\alpha_1$ proteinase inhibitor therapy on computed tomography lung density in patients with $\alpha_1$ antitrypsin deficiency. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2386-2397.	1.1	9
20	Respiratory impairment impacts QOL in osteogenesis imperfecta independent of skeletal abnormalities. <i>Archives of Osteoporosis</i> , 2020, 15, 153.	1.0	9
21	Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. <i>International Journal of COPD</i> , 2021, Volume 16, 2983-2996.	0.9	8
22	Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. <i>Scientific Reports</i> , 2022, 12, 5207.	1.6	8
23	Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency. <i>Annals of the American Thoracic Society</i> , 2016, 13, S370-S373.	1.5	6
24	&lt;p&gt;Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 2389-2397.	0.9	5
25	&lt;p&gt;Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 3313-3322.	0.9	5
26	Limitations and Challenges of Conducting Budget Impact Analyses in Rare Diseases: A Case Study of Alpha-1 Antitrypsin Deficiency. <i>Value in Health Regional Issues</i> , 2020, 23, 70-76.	0.5	5
27	Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency. <i>Thorax</i> , 2021, 76, 134-143.	2.7	5
28	Might your respiratory patient have alpha-1 antitrypsin deficiency?. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2015, 44, 463-464.	0.8	2
29	Home-Based Multicomponent Intervention Increases Exercise Activity and Improves Body Mass Index: Results of a 5-Year Randomized Trial Among Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2020, 8, 7-18.	0.5	2
30	Managing the Alpha-1 patient in the ICU: Adapting broad critical care strategies in AATD. <i>Journal of Critical Care</i> , 2019, 54, 212-219.	1.0	1